"The U.K. pharmaceutical company said it had signed an agreement with Verily Life Sciences LLC, formerly Google Life Sciences, to create Galvani Bioelectronics. It said the pair would spend as much as £540 million ($714 million) over seven years on the venture, provided they succeeded in hitting various milestones along the way. Glaxo will control 55% of the new company and Verily will hold the rest.Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture - WSJ
Many biological processes are controlled by electrical signals transmitted from the nervous system to the body’s organs. Glaxo said early-stage research in its laboratories suggested that distortions of those signaling pathways were involved in several long-term diseases including diabetes, asthma and arthritis."
Tuesday, August 02, 2016
Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture - WSJ
Check the full article for more on Alphabet's life sciences-related investments